Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tram T Tran

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionJordan J Feld, Ira M Jacobson, Christophe Hézode, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Pageof 7